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ABSTRACT
Objective. To assess the impact of the 
knee joint inflammation, detected by 
ultrasonography (US), on functional 
disability in patients with recent-onset 
inflammatory polyarthritis (IP).
Methods. We included patients who 
had IP for less than 12 months and 
who had more than 5 swollen joints. 
All patients were assessed clinically 
at baseline. US was used to identify 
joint inflammation at multiple joint 
sites including: hands, wrists, elbows, 
shoulders, knees, ankles and feet. Joint 
group involvement was defined when at 
least one joint showed intra-articular 
signs of inflammation (synovial fluid 
abnormalities and/or synovial hyper-
trophy), according to the OMERACT 
definitions. Functional disability was 
measured using the health assessment 
questionnaire (HAQ) score. All pa-
tients with complete clinical and US 
data were included in the analysis.
Results. Patients with US knee in-
volvement showed more active and 
severe disease at baseline. The mean 
difference of HAQ between patients 
with and without US knee inflammation 
was 0.42 (95%CI 0.22, 0.62; p<0.001). 
This difference was still clinically and 
statistically significant even after con-
trolling for disease extension and pat-
tern of joint involvement. US shoulder 
involvement was also significantly and 
independently associated with higher 
mean HAQ scores.
Conclusion. US knee involvement is 
associated with higher disability in IP 
at first presentation. US is a good tool 
to help in the differentiation of patients 
with recent-onset IP with different dis-
ease severity. 
Introduction
Although a number of effective drugs 
and therapeutic strategies are available 
for treating inflammatory polyarthri-
tis (IP), including rheumatoid arthritis 
(RA), the early diagnosis and identifi-
cation of reliable prognostic indicator 
remain an ongoing challenging (1, 2).
Several studies have focused on demo-
graphic, serological, genetic and ra-
diographic variables as diagnostic and 
prognostic factors for IP (3-6). The ex-
tent and sites of joint involvement are 
regarded as additional diagnostic and 
prognostic factors (7-9).
A few studies have investigated the im-
pact of clinical involvement of the knee 
joint in IP, including RA. Overall, these 
studies indicate that patients with early 
IP, including RA, have a more severe 
disease in terms of functional disability 
and worse functional prognosis (10-12). 
These results indicate that patients with 
IP who have clinical involvement of the 
knee joint represent a subset of patients 
with more severe disease. However, it 
is known that clinical examination is far 
from accurate when it comes to identi-
fying joint inflammation compared to 
more sensitive and specific radiological 
techniques, such as musculoskeletal ul-
trasonography (US) (13-15). US is well 
demonstrated to be a valid and reliable 
tool for the assessment of joint inflam-
mation and therefore could be used to 
sub-stratify IP patients with different 
disease severity (16-20).
In this work we systematically applied 
US to identify joint inflammation at 
the knee joint site in patients with re-
cent-onset IP in order to investigate the 
impact of knee joint involvement on 
outcome such as functional disability. 
For this purpose we included a sample 
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of patients with recent-onset IP from 
an inception cohort of early arthritis 
and we cross-sectionally analysed the 
baseline association between US knee 
involvement and the health assessment 
questionnaire (HAQ) score.
Materials and methods
Setting and participants
Patients with IP and with symptom 
duration less than 12 months were in-
cluded in the study. All subjects gave 
written consent. For the purpose of this 
study we only included patients with 
RA or undifferentiated polyarthritis 
who had at least 5 swollen joints on the 
44-joint count at baseline evaluation.
Baseline data from patients with com-
plete US examination were used for the 
cross-sectional analyses.
Patient assessment
The clinical assessment included: ten-
der and swollen joint count (TJC, SJC) 
on 44 and 28 joints, visual analogue 
scale (VAS) for pain, patient’s global 
assessment (PGA), physician’s global 
assessment (PhGA) and global health 
assessment (GH). Disease activity was 
assessed using the disease activity score 
(DAS) on 28-joint count (21). Labora-
tory tests included rheumatoid factor 
(RF), anti-citrullinated peptide antibod-
ies (ACPA), erythrosedimentation rate 
(ESR) and C-reactive protein (CRP). 
Functional disability was assessed by 
the Italian version of the HAQ (22). 
The American College of Rheumatol-
ogy (ACR; formerly the American 
Rheumatism Association) 1987 criteria 
for RA (23) were applied cross-section-
ally at baseline.
Musculoskeletal ultrasonography 
US assessment was performed blindly 
by a single experienced operator, using 
a Logiq 9 (General Electrics Medical 
Systems, Milwaukee, WI) with multi-
frequency linear probes (8-14 MHz) 
according to the European League 
Against Rheumatism (EULAR) guide-
lines (24). The scanning protocol of 
metacarpophalangeal (MCP), proxi-
mal interphalangeal (PIP) wrist, knee, 
elbow, shoulder, ankle and metatarso-
phalangeal (MTP) joints was performed 
as detailed elsewhere (25).
The presence of joint effusion (JE) and 
synovial hypertrophy (SH) was identi-
fied in each joint as abnormal anechoic/
hypoechoic intra-articular material ac-
cording to the OMERACT definitions 
(26). Grey-scale (GS) synovitis was 
defined as the presence of JE and/or 
SH. JE and SH were subjectively grad-
ed from 0 to 3 (0=normal; 1=mild; 2 
= moderate; 3=marked) (25, 27). GS 
synovitis was graded by summing the 
scores of  both JE and SH.
Synovial power Doppler (PD) was as-
sessed by selecting a region of interest 
that included the bony margins, joint 
space and a variable view of surround-
ing tissues (depending on the joint 
size). PD calibrations were adjusted at 
the lowest permissible pulse repetition 
frequency to maximise sensitivity and 
were taken as a constant for the same 
joint in different patients. Doppler fre-
quency was set higher for the study of 
small joints and superficial tissues, and 
lower for deep structures. Colour gain 
was set just below the level that causes 
the appearance of noise artefacts. Flow 
was demonstrated in two perpendicular 
planes and confirmed by pulsed wave 
Doppler spectrum to exclude artefacts. 
The PD signal was subjectively graded 
on a semi-quantitative scale from 0 to 
3 (0=absence or minimal flow; 1=mild: 
single vessel signal; 2=moderate: con-
fluent vessels; 3=marked: vessel sig-
nals in >50% of the joint area) on the 
image with the maximal enhancement 
on PD (25, 28, 29).
A joint was considered involved when 
score 1 GS synovitis and/or PD signal 
were detected by US. 
The involvement of each joint group 
(wrists, MCPs, PIPs, elbows, shoulders, 
knees, ankles, MTPs) was defined as the 
presence of at least 1 positive joint.
Statistical methods
Summary statistics of mean and stand-
ard deviation (SD) or median and 
interquartile range (IQR), when ap-
propriate, were presented for continu-
ous variables. Baseline differences 
between patients with and without US 
knee involvement were tested using the 
Wilcoxon’s rank sum test for continu-
ous variables and the chi-square test for 
categorical variables.
Only patients with complete clinical 
and US data at baseline were included 
in analysis.
To explore the relationship between the 
involvement of the knee and HAQ we 
applied linear regression. This approach 
allowed us to estimate the HAQ mean 
difference (MD) between patients with 
and without US knee involvement and 
95% confidence interval (95%CI), even 
correcting for relevant confounders.
The expected violation of distribu-
tive normality of the outcome variable 
(HAQ) was allowed, due to the robust-
ness of the linear regression model. To 
verify this, we also performed a quantile 
regression, and the result from the lin-
ear regression model was retained only 
in case of consistency of the results.
Following this approach we firstly 
carried out an unadjusted analysis fol-
lowed by sequential adjusted analysis 
aimed at controlling for potential con-
founders and to identify the specific 
impact of the site of involvement on 
functional disability. In the first step 
we corrected for potential confound-
ers such as age and sex; in the second 
step we also checked for the extension 
of joint inflammation; and in the third 
step also for every other specific joint 
site involvement. 
All analyses were conducted using 
Stata version 11 (StataCorp, College 
Station, TX).
Results
Study sample 
We have cross-sectionally analysed a to-
tal of 228 subjects with early-onset IP at 
baseline evaluation. Their main clinical 
characteristics are summarised in Table 
I. Overall, the study sample included 
patients median (IQR) age of 62 (51–
72) years, higher prevalence of female 
gender (71.9%), median (IQR) symp-
toms duration of 3.5 months (2.3–6.5), 
with severe disease activity (mean (SD) 
DAS28 5.2 (1.8), and moderate func-
tional disability (median[IQR] HAQ 
1.250 [0.687–1.875]). The majority of 
patients (85.5%) were untreated with 
DMARDs or oral steroids at baseline.
 
Clinical and ultrasonographic 
joint involvement 
Of the 228 patients, 146 (64.0%) pre-
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sented with US involvement of either 
or both knees. US involvement was 
detected in 132 (57.9%) right and in 
125 (54.4%) left knee joints. Involve-
ment was symmetrical in 110 (48.2%) 
patients. Detailed analysis of US fea-
tures of patients showed that in most 
of them the joint had low scores for 
effusion and hypertrophy. PD signal 
was detected in a very low percentage 
of patients (4.8% for the right knee and 
3.5% for the left), and again with low 
scores (Table II).
Clinical involvement of either or both 
knees was found in the 47.7% patients 
(unilateral 33.1% and bilateral 14.6%). 
US was more sensitive (proportion 
difference = 0.16 [95%CI 0.06–0.26]) 
than clinical examination. Using US as 
reference standard clinical examination 
showed a low sensitivity (57.7%) and a 
low specificity (70.9%) for the detec-
tion of joint inflammation.
US involvement of the other joint 
groups was recorded: MCP in 207 
(91%), MTP in 195 (85%), wrists in 
177 (78%), PIP in 171 (75%), ankles 
in 123 (54%), elbows in 34 (15%) and 
shoulders in 21 (9%) patients. 
Impact of US knee joint involvement 
on functional disability
Age, sex distribution, disease duration, 
autoantibody (RF and/or ACPA) dis-
tribution, tender joint count, VAS pain 
and GH, and previous treatment were 
not different between patients with and 
without knee US involvement. The SJC, 
both on 28 and 44 joints (p<0.001), 
DAS28 (p<0.001), PGA (p=0.04), 
PhGA (p<0.001), ESR (p=0.003), CRP 
(p=0.003) and HAQ at the baseline 
visit (p=0.001) significantly differed 
comparing the two groups and were 
higher in the group of patients with US 
involvement of the knee (Table I).
We focused further analysis on the re-
lationship between HAQ US-detected 
knee involvement.
In the first unadjusted analysis, subjects 
with US knee involvement showed a 
significantly higher HAQ score com-
pared to those without US knee in-
volvement (MD 0.42 [95%CI 0.22-
0.62]) (Table III). This effect was also 
independent of the age and gender.
Since subjects with US knee involve-
ment showed a wider degree of disease 
involvement, we analysed the effect of 
the knee joints correcting for the number 
of swollen joints. On equal swollen 
joints, the involvement of the knee ac-
counted for a clinically and statistically 
significant mean increase of the HAQ 
score of 0.27 [95%CI 0.07–0.47].
When including the analysis of US in-
volvement of other joint groups in the 
model, presence of an affected knee 
still significantly influenced the HAQ 
score. In this model, age and the 44-
swollen joint count resulted in a sig-
nificant influence; another joint group 
with a likewise significant impact was 
the shoulder (Table IV).
Discussion
This study sought to determine the im-
pact of US knee involvement on func-
tional disability in an inception cohort 
of IP. This is the first study specifically 
investigating such relationship. 
We found that involvement of the knee 
joint detected by US identified a sub-
group of patients with a significant 
lower functional disability as measured 
by HAQ score.
Comparing subjects with and without US 
knee involvement, we found a number 
of further clinical differences that could 
account for the increased mean HAQ 
score. In particular the higher number of 
swollen joints in patients with US knee 
involvement suggested that US knee 
involvement could be a “biomarker” of 
the extension of the disease rather than 
Table I. Patients’ characteristics.
 US knee involvement
 
 All subjects Yes No   
US Knee involvement 228 146 82
Age, median (IQR) 62 (51–72) 62 (52–73) 60 (49–68)
Gender female, n (%) 164 (71.9) 101 (69.1) 63 (76.8)
Disease duration, median (IQR) 3.5 (2.3–6.5) 3.7 (2.3–6.4) 2.9 (2–6.5)
RF, n (%) 70 (31)  41 (28) 29 (35)
ACPA, n (%)§ 54 (24) 33 (23) 21 (26)
ACR criteria, n (%)** 172 (75.4) 120 (82.2) 52 (63.4)
DAS28, mean (SD)*** 5.2 (1.8) 5.4 (1.2) 4.8 (1.1)
VAS pain, median (IQR)* 57 (48–80) 60 (50–80) 53 (40–76)
VAS patient, median (IQR)*** 60 (46–80) 63 (47–80) 51 (45–75)
VAS physician, median (IQR)* 45 (33–60) 49 (38-62) 40 (29–50)
VAS GH, median (IQR) 54 (50–71) 52 (50–70) 55 (50–74)
SJC44, median (IQR)*** 11 (8–18) 14 (9–19) 9 (7–13)
TJC44, median (IQR)*** 13 (6–18) 14 (6–19) 11 (5–18)
SJC28, median (IQR)*** 9 (6–13) 10 (7–14) 6 (4–10)
TJC28, median (IQR)*** 8 (3–14) 9 (4-15) 8 (3–12)
ESR, median (IQR)*** 25 (14–42) 28 (16–48) 21 (11–34)
CRP, median (IQR)*** 0.7 (0.3–2.4)  1.1 (0.3–3.1) 0.5 (0.3–1.3)
HAQ score, median (IQR)** 1.3 (0.7–1.9) 1.4 (0.8-2) 0.9 (0.5–1.5)
Wilcoxon signed rank sum test * p<0.05 **p<0.01 ***0<0.001
RF: rheumatoid factor; ACPA: anti-citrullinated peptide antibodies; ACR: American College of 
Rheumatology; DAS: disease activity score; VAS: visual analogue scale; GH: global health assessment; 
TJC, SJC: tender and swollen joint count; ESR: erythrosedimentation rate; CRP: C-reactive protein; 
HAQ: health assessment questionnaire. 
Table II. Musculoskeletal ultrasound findings at the knee joints.
 Grade Joint effusion Synovial Power Doppler
   hypertrophy
 Grade Joint effusion Synovial hypertrophy Power Doppler
Right knee, n(%) 0 96 (42.1) 189 (82.8) 217 (95.1)
 1 110 (48.2) 25 (10.9) 9 (3.9)
 2 19 (8.3) 7 (3.0) 2 (0.8)
 3 3 (1.3) 7 (3.0) 0
Left knee, n(%) 0 105 (46.0) 193 (84.6) 220 (96.4)
 1 109 (47.8) 24 (10.5) 8 (3.5)
 2 14 (6.1) 5 (2.1) 0
 3 0  6 (2.6) 0
452
IMAGING US knee in early arthritis / C.A. Scirè et al.
identifying a subgroup of patients with 
a qualitatively different distribution of 
joint inflammation. Although adjusted 
analyses confirmed that swollen joints 
acted as confounder of the relationship 
between for US knee involvement and 
functional disability, US knee involve-
ment retained both statistical and clini-
cally significant effects on HAQ score. 
To rule out the possibility that the ef-
fect of knee involvement was due to a 
relationship with one or more different 
joint groups we also performed a multi-
variate analysis including all joint sites 
included in our US protocol, showing 
again significant differences between 
subjects with and without knee in-
volvement.
Previous studies have focused on the 
impact of the clinical involvement of 
the knee. In a cross-sectional study on 
established RA, the knee involvement 
accounted for a valuable proportion of 
reported pain and functional disabil-
ity scales (11). In a prospective study 
of an inception cohort of IP, the knee 
involvement resulted independently 
associated with future development of 
functional disability both in the over-
all population of IP and even more in 
the subgroup of patients who fulfilled 
classification criteria for RA (10). In a 
further cohort study of early RA, the in-
volvement of large joint – in particular, 
the knee – was demonstrated to longi-
tudinally associate with a worse radio-
logical outcome after 12 months (12). 
Other studies investigating the longi-
tudinal effect of the clinical involve-
ment of the knee in the early phases 
of IP in terms of different clinical out-
comes showed less consistent results. 
In particular, the knee involvement did 
not appear as a significant predictor of 
relevant outcomes such as the persist-
ency of symptoms (and erosiveness) 
(8) and the fulfilment ACR criteria 
for RA (9). The study of Visser et al. 
analysed patients with early arthritis in-
cluding mono- and oligoarthritis, while 
the study of van der Helm-van Mil et 
al. only included early undifferentiated 
arthritis. Selecting a population of both 
mono-oligoarthritis and polyarthritis 
is not clearly a good choice to explore 
the effect of knee involvement, as the 
intrinsic relationship between knee and 
monoarthritis may bias the prognostic 
value of the knee toward the effect of 
monoarthritis by itself. For this reason, 
we selected a population of polyarthri-
tis who had at least 5 swollen joints 
(30). The particular setting of the in-
ception cohort allowed us to investigate 
a homogeneous population of untreated 
patients. 
US allowed us to easily assess multiple 
sites during the same session.
Our study reconfirmed the higher sen-
sitivity of US in the detection of joint 
inflammation over clinical examina-
tion. Furthermore, in our study sam-
ple we detected more prevalent low 
US scores of knee involvement. These 
findings indicate that our analysis 
mostly investigated the effect of mild 
and subclinical knee involvement. As 
a matter of fact, although a significant 
effect in terms of functional disability 
was demonstrable also for the clinical 
involvement of the knee, it was weaker 
and disappeared when corrected for the 
extension of the disease (not shown). 
This strengthens the relevance of using 
US to detect subclinical joint inflam-
mation at the knee site.
From an analysis of the effect on HAQ 
of different joint groups, the shoulder 
showed the highest impact. This find-
ing is in keeping with the previous 
reported association between clinical 
involvement of the shoulder and risk 
of future structural damage in early RA 
(12). Conversely, it contrasts with the 
lack of association between shoulder 
involvement and disability observed in 
a wide population-based inception co-
hort of IP (10). As discussed by Wiles 
et al. this lack of evidence could be due 
to inaccurate clinical examination in 
detecting shoulder involvement. Our 
study therefore supports the use of US 
as a tool for detecting shoulder involve-
ment in IP. 
This study has some limitations. The 
study population did not include some 
specific forms of IP, such as seronega-
tive spondyloarthropathy. This selec-
tion may limit the generalisability of 
our findings to the overall population 
of recent-onset IP. A second limitation 
relates to the choice of the HAQ score 
as an outcome measure. Since specific 
domains within the HAQ are devoted 
to knee involvement, some degree of 
association could be expected. Finally, 
US findings may be non-specific for 
Table III. Crude and adjusted estimates of mean difference in HAQ between subjects with 
and without US knee involvement.
 Mean HAQ 95%CI p-value
 difference 
US knee 0.42 0.22–0.62 <0.0001
US knee* 0.39 0.20–0.59 <0.0001
US knee# 0.27 0.07–0.47 0.008
*adjusted for age and sex.
#adjusted for age, sex, swollen joints on 44.
Table IV. Multivariable adjusted estimates of mean difference in HAQ between subjects 
with and without specific joint group US involvement.
 Mean HAQ 95%CI p-value
 difference 
US knee# 0.25 0.05–0.46 0.02
US wrist# 0.11 -0.13–0.35 0.4
US MCP# -0.10 -0.45–0.25 0.6
US PIP# -0.09 -0.32–0.14 0.4
US elbow# -0.10 -0.36–0.17 0.5
US shoulder# 0.56 0.23–0.89 0.001
US ankle# 0.08 -0.12–0.27 0.4
US MTP# -0.01 -0.28–0.26 0.9
#adjusted for age, sex, swollen joints on 44.
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inflammation related to polyartritis 
alone and could be related to degenera-
tive processes.
In conclusion, this study confirms the 
impact of knee involvement on the dis-
ease severity of IP, and supports the use 
of US in the stratification of patients 
with recent-onset IP with different dis-
ease severity.
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